Is Microdosing Ozempic the Next Longevity Breakthrough?
Siim Land — Is Microdosing Ozempic the Next Longevity Breakthrough?
Channel: Siim Land · Our label: Longevity creator · Source: youtube.com/watch?v=dPQMQPDLvKI
What this video covers
Everyone knows GLP-1s are extremely effective for weight loss. Every week, it feels like another celebrity, influencer, or family member who used to be overweight suddenly becomes lean after using them. But, I’m very surprised by how many normal-weight people are using GLP-1s as well. The reason most of these people take GLP-1s is to make it easier for them to stay lean.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- A 2023 phase 2 clinical trial on retatrutide saw that it resulted in 24% mean weight loss at 48 weeks, compared to semaglutide’s 15% weight loss at 68 weeks, and tirzepatide’s 21% weight loss.
- When it comes to neurodegenerative conditions, then clinical trials on people with Alzheimer’s disease have failed to slow clinical disease progression, despite some beneficial changes in biomarkers.
- GLP-1s can lower inflammation and neuroinflammation by improving insulin resistance.
- However, there are no long-term health studies on healthy people.
- So, in this particular study, if people had taken GLP-1s, they would have been able to adhere to the full 25% calorie deficit for the entire study, probably.
- There’s some preclinical evidence that semaglutide and other GLP-1s help to regenerate the the of joints independent of the weight loss and metabolic health benefits.
Read next
- Semaglutide — more videos
- Tirzepatide — more videos
- Retatrutide — more videos
- All videos from this channel
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.